Hims' new partnership with Novo Nordisk aims to sustain growth, but competition from direct-to-consumer platforms raises ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

The downbeat outlook came as Hims & Hers moves away from providing a version of the weight-loss drug in Novo Nordisk's (NVO) Wegovy and Ozempic and makes changes its plan for sexual health products.

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.